857371 | VU0359595

(1R,2R)-N-([S]-1-{4-[5-bromo-2-oxo-2,3-dihydro-1H-benzo(d)imidazol-1-yl]piperidin-1-yl}propan-2-yl)-2-phenylcyclopropanecarboxamide


Powder

Size SKU Packaging Price
1mg 857371P-1mg 857371P-1mg 1 x 1mg $137.00
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
Please select an option above.
${sku} - ${concentration}

VU0359595

VU0359595

(1R,2R)-N-([S]-1-{4-[5-bromo-2-oxo-2,3-dihydro-1H-benzo(d)imidazol-1-yl]piperidin-1-yl}propan-2-yl)-2-phenylcyclopropanecarboxamide

VU0359595 has been shown to selectively inhibit the PLD1 isoform at nM levels (see data below).
 
Hygroscopic
No
Light Sensitive
No
Molecular Formula
C25H29BrN4O2
Percent Composition
C 60.36%, H 5.88%, Br 16.06%, N 11.26%, O 6.43%
Purity
>99%
Stability
1 Years
Storage Temperature
-20°C
CAS Number
1246303-14-9
CAS Registry Number is a Registered Trademark of the American Chemical Society
Molecular Weight
497.427
Exact Mass
496.147
Synonyms

EVJVU0359595

Bruntz, R.C., H.E. Taylor, C.W. Lindsley, and H.A. Brown. (2013). Phospholipase D2 mediates survival signaling through direct regulation of Akt in glioblastoma cells. J Biol Chem [PubMed] Lewis, J.A., Scott, S.A., Lavieri, R., Buck, J.R., Selvy, P.E., Stoops, S.L., Armstrong, M.D., Brown, H.A., and C.W. Lindsley. (2009) Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I. Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorganic and Medicinal Chemistry Letters. 19, 1916-1920. [PubMed]